As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 86-2967193 (I.R.S. Employer Identification No.) 4475 Executive ...

Core Insights - Connect Biopharma has expanded its Board of Directors from six to seven members with the appointment of Jim Schoeneck, who brings over 40 years of experience in drug development and commercialization [1][2][3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD) [4] - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for treating acute exacerbations of asthma and COPD [4] Leadership and Expertise - Jim Schoeneck's appointment is expected to enhance the company's strategic and commercial capabilities, particularly in advancing the development and commercialization of rademikibart [2][3] - Schoeneck has held leadership positions in various biotech firms and has a strong background in guiding companies through significant transformations [3] Product Development - Rademikibart is positioned to address the needs of millions of patients with asthma or COPD who experience acute exacerbations annually [2] - The company anticipates clinical data from its Phase 2 Seabreeze STAT studies in the first half of 2026 [2]

Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Wednesday, while the Dow rose 0.18% to 44,319.31, the NASDAQ increased 0.62% to 20,545.29, and the S&P 500 climbed 0.31% to 6,245.11 [1] - Communication services shares increased by 1.1%, while consumer staples stocks dipped by 1% [1] Commodity News - Oil prices rose by 0.6% to $68.74, while gold prices fell by 0.1% to $3,315.70. Silver decreased by 0.4% to $36.610, and copper dropped by 3.8% to $5.4715 [5] European Market - European shares showed positive performance, with the eurozone's STOXX 600 rising 0.71%, Spain's IBEX 35 Index increasing by 1.07%, London's FTSE 100 gaining 0.13%, Germany's DAX 40 up by 1.32%, and France's CAC 40 rising by 1.40% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei gaining 0.33%, while Hong Kong's Hang Seng fell by 1.06%, China's Shanghai Composite declined by 0.13%, and India's BSE Sensex decreased by 0.21% [7] Company Developments - Calidi Biotherapeutics, Inc. saw its shares surge by 353% to $1.48 due to advancements in cancer treatment [9] - SU Group Holdings Limited's shares increased by 155% to $1.1609 after securing an HK$88.5 million hospital contract [9] - Evoke Pharma, Inc. shares rose by 171% to $7.20 following a notice of allowance for a U.S. patent application [9] - Bitmine Immersion Technologies, Inc. shares dropped by 47% to $59.22 after filing for a mixed shelf [9] - RxSight, Inc. shares fell by 42% to $7.39 after revising its 2025 revenue guidance downwards [9] - Vertical Aerospace Ltd. shares decreased by 31% to $4.77 after announcing a $60 million public offering at $5/share [9] Inventory Data - U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May, aligning with preliminary estimates [11] - U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, marking the largest gain since January [11]

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $3.9 million to support its clinical programs and working capital needs [4]. Group 1: Offering Details - The company issued and sold 3,325,000 shares of common stock and pre-funded warrants to purchase up to 2,728,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrants was $0.65, with pre-funded warrants priced at $0.649 [2]. - The Series G warrants have an exercise price of $0.6954 per share and are exercisable six months from issuance, expiring seven and a half years after the initial exercise date [2]. Group 2: Use of Proceeds - Calidi intends to utilize the net proceeds from the offerings for working capital, general corporate purposes, and to advance its pre-clinical and clinical programs [4]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted immunotherapies using proprietary technology to enhance the immune system's ability to fight cancer [8]. - The company employs novel stem cell-based platforms to deliver oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [8].

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 2834 Primary Standard Industrial Classification Code Number Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (IRS Employer Identification No.) Delaware 86-2967193 4475 Executive Drive, Suite 200 San Diego, CA 92121 (858) 794-9600 (Address, including zip code, and telepho ...

As filed with the Securities and Exchange Commission on April 15, 2024. Registration No. 333-276741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 2834 86-2967193 (I.R.S. Employer Identification No.) 4475 Executive Driv ...

As filed with the Securities and Exchange Commission on April 8, 2024. Registration No. 333-276741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 86-2967193 (I.R.S. Employer Identification No.) 4475 Executive Drive, Suite 200, San Diego, Calif ...

Washington, D.C. 20549 As filed with the Securities and Exchange Commission on April 2, 2024. Registration No. 333-276741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Allan J. Camaisa Chief Executive Officer c/o Calidi Biotherapeutics, Inc. 4475 Executive Drive, Suite 200, San Diego, CA 92121 Telephone: (858) 794-9600 (Name, address, including zip code, and telephone number, including ar ...

As filed with the Securities and Exchange Commission on March 29, 2024. Registration No. 333-276741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 2834 86-2967193 (I.R.S. Employer Identification No.) 4475 Executive Driv ...

As filed with the Securities and Exchange Commission on February 7, 2024. Registration No. 333-276741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Calidi Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Allan J. Camaisa Chief Executive Officer c/o Calidi Biotherapeutics, Inc. 4475 Executive Drive, Suite 200, San Diego, CA 92121 Telephone: (858) 794-9600 (Name, address, i ...